ArticleScientific reports2026
Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Interventions aimed at the diagnosis of viral hepatitis in migrants from countries with high prevalence rates are essential to achieve the elimination of viral hepatitis. The objective was to perform a cost-effectiveness analysis of a community screening strategy for hepatitis B and C virus (HBV and HCV) infections versus no intervention in migrant populations in Catalonia. HBV and HCV decision trees for the community strategy (from community screening to simplified access to care and treatment) and Markov models to simulate hepatitis B and C disease progression were developed. Sensitivity analyses were performed with the parameters with the highest uncertainty. Among the 2291 people screened, 74 and 21 cases of HBV and HCV infection were diagnosed, which avoided 79% and 62% of liver complications related to HBV and HCV, respectively. Community HCV screening showed an incremental cost of €13,999/patient versus no intervention and 2.98 quality-adjusted life years (QALYs) per patient, resulting in an incremental cost‒utility ratio of €4692/QALY gained. The HBV strategy was dominant. The distribution of HCV patients across different fibrosis stages had a greater impact on sensitivity analyses. Implementing a community screening strategy, which also increased awareness of HBV and HCV infections and treatment in migrant populations, is cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.